Fampyra: new option for walking disability in MS

Fampyra (fampridine) is indicated for use in multiple sclerosis to improve walking in patients who have a walking disability (EDSS 4-7).

Recommended dose is twice a day, taken 12 hours apart, without food
Recommended dose is twice a day, taken 12 hours apart, without food
PHARMACOLOGY

Fampridine is a potassium channel blocker. It prolongs channel repolarisation which enhances action potential formation in demyelinated axons, leading to improved neurological function.1

CLINICAL STUDIES

The efficacy of fampridine to improve walking was established in two double-blind studies in which patients with multiple sclerosis were randomised to receive prolonged-release fampridine 10mg twice daily or placebo. Completion of a timed 25-foot walk was used as the primary efficacy endpoint in both studies. Patients who showed a faster walking speed on at least 3 out of 4 occasions, in comparison to their walking speed before treatment, were considered to have responded to treatment.1,2

In one study (n=296), 34.8% of patients taking fampridine responded to the treatment, with an average increase in walking speed of 26.3% vs 5.3% on placebo (p<0.001). The other study (n=237) showed similar results with 42.9% responding to treatment and an increase in walking speed of 25.3% vs 7.8% (p<0.001).1-3

Treatment should be initiated and supervised by a specialist doctor experienced in the management of multiple sclerosis. Treatment should be limited to two weeks by which time any clinical benefits should have been identified. A timed walking test should be used to evaluate improvement after two weeks. If no benefits are observed, Fampyra should be discontinued.1

REFERENCES

1.    Fampyra Summary of Product Characteristics, 2011.
2.    Goodman et al. Lancet 2009; 373: 732–8.
3.    Goodman et al. Ann Neurol 2010; 68: 494–502.

View Fampyra drug record

Further information: Biogen Idec

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases